A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients
Open Access
- 1 September 2005
- journal article
- clinical trial
- Published by Elsevier in Clinical Microbiology & Infection
- Vol. 11 (9) , 736-743
- https://doi.org/10.1111/j.1469-0691.2005.01215.x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus diseaseTransplant Infectious Disease, 2004
- Detection of ganciclovir resistance after valacyclovir‐prophylaxis in renal transplant recipients with active cytomegalovirus infectionJournal of Medical Virology, 2004
- Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas–kidney, and pancreas transplantationClinical Transplantation, 2004
- Onset and duration of cytomegalovirus immediate early 1 mRNA expression in the blood of renal transplant recipientsJournal of Medical Virology, 2003
- Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal TransplantationPharmacoEconomics, 2000
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999
- The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: Implications for organ allocationAmerican Journal of Kidney Diseases, 1997
- Management of Cytomegalovirus Infection IN Solid-Organ Transplant RecipientsImmunological Investigations, 1997
- Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacyAntiviral Research, 1995
- A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal AllograftsNew England Journal of Medicine, 1989